Download PDF
Klinische Neurophysiologie 2021; 52(03): 167-179
DOI: 10.1055/a-1528-3511
Übersicht

Pädiatrische epileptische Enzephalopathien mit Manifestation oberhalb des Neugeborenenalters: ein Up-date

Update on Epileptic Encephalopathies of Infancy and Childhood
Regina Trollmann
1   Abteilung Neuropädiatrie und Sozialpädiatrisches Zentrum, Kinder-und Jugendklinik am Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen
,
Ingo Borggräfe
2   Abteilung für Pädiatrische Neurologie, Entwicklungsneurologie und Sozialpädiatrie, Dr. von Haunersches Kinderspital, LMU Klinikum München, München
3   Interdisziplinäres Epilepsiezentrum, LMU Klinikum München, München
,
Wolfgang Müller-Felber
2   Abteilung für Pädiatrische Neurologie, Entwicklungsneurologie und Sozialpädiatrie, Dr. von Haunersches Kinderspital, LMU Klinikum München, München
,
Ulrich Brandl
4   Klinik für Neuropädiatrie, Universitätsklinikum Jena, Jena
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Entwicklungs-und epileptische Enzephalopathien manifestieren sich überwiegend bereits im Säuglings-und frühen Kleinkindesalter. Mit der neuen ILAE-Klassifikation der Epilepsien konnten epileptische Enzephalopathien sowohl hinsichtlich des elektroklinischen Phänotyps als auch des ätiologischen Spektrums und assoziierter Komorbiditäten genauer definiert werden. Einige elektroklinischer Entitäten wie das West-Syndrom oder das Dravet-Syndrom können auf der Basis ihres Genotyps inzwischen als spezifische Enzephalopathien klassifiziert werden. Das EEG stellt eine wichtige Zusatzdiagnostik in der Abklärung einer epileptischen Enzephalopathie dar. Es hat einen besonderen Stellenwert für die Diagnose von Komplikationen wie z. B. subklinischer Anfälle oder eines Status epilepticus sowie für ein adäquates Therapiemonitoring. Der Betrag fasst anhand ausgewählter pädiatrischer Epilepsiesyndrome aktuelle Aspekte zur Komplexität der pädiatrischen epileptischen Enzephalopathien und den Stellenwert der EEG-Diagnostik zusammen.

Abstract

Developmental and epileptic encephalopathies represent complex and neurodegenerative disorders characterized by onset of refractory seizures usually in the first year of life and associated with motor and intellectual disability. The new ILAE classification of seizures and epilepsies proposed a revised definition of epileptic encephalopathies including electro-clinical phenotype as well as etiological spectrum and associated comorbidities. Modern genetic techniques led to the identification of a precise genotype in several electro-clinical syndromes such as West syndrome and Dravet syndrome. EEG continues to play a specific role as an additional tool in diagnosis and management of epileptic encephalopathies with special focus on the diagnosis of complications such as subclinical seizures and status epilepticus as well as treatment monitoring. This article reviews current aspects of complex pediatric epileptic encephalopathies and the significance of EEG monitoring.

Schlüsselwörter

West-Syndrom - Dravet-Syndrom - Landau-Kleffner-Syndrom - CSWS - Lennox-Gastaut-Syndrom

Key words

West syndrome - Dravet syndrome - Landau-Kleffner syndrome - CSWS - Lennox-Gastaut syndrome


Publication History

Article published online:
13 September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Fisher RS, Cross JH, French JA. et al Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58: 522-530
    CrossrefPubMedGoogle Scholar
  • 2 Scheffer IE, Berkovic S, Capovilla G. et al ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58: 512-521
    CrossrefPubMedGoogle Scholar
  • 3 Symonds JD, McTague A. Epilepsy and developmental disorders: Next generation sequencing in the clinic. Eur J Paediatr Neurol 2020; 24: 15-23
    CrossrefPubMedGoogle Scholar
  • 4 Wolff M, Brunklaus A, Zuberi SM. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond. Epilepsia 2019; 60: S59-S67
    CrossrefPubMedGoogle Scholar
  • 5 Jozwiak S, Kotulska K, Wong M. et al Modifying genetic epilepsies - Results from studies on tuberous sclerosis complex. Neuropharmacology 2020; 166: 107908
    CrossrefPubMedGoogle Scholar
  • 6 Nariai H, Hussain SA, Bernardo D. et al Scalp EEG interictal high frequency oscillations as an objective biomarker of infantile spasms. Clin Neurophysiol 2020; 131: 2527-2536
    CrossrefPubMedGoogle Scholar
  • 7 Lux AL. Latest American and European updates on infantile spasms. Curr Neurol Neurosci Rep 2013; 13: 334-341
    CrossrefPubMedGoogle Scholar
  • 8 Pavone P, Polizzi A, Marino SD. et al West syndrome: a comprehensive review. Neurol Sci 2020; 41: 3547-3562
    CrossrefPubMedGoogle Scholar
  • 9 Wirrell EC, Shellhaas RA, Joshi C. et al How should children with West syndrome be efficiently and accurately investigated? Results from the National Infantile Spasms Consortium. Epilepsia 2015; 56: 617-625
    CrossrefPubMedGoogle Scholar
  • 10 Kothare SV, Singh K, Chalifoux JR. et al Severity of manifestations in tuberous sclerosis complex in relation to genotype. Epilepsia 2014; 55: 1025-1029
    CrossrefPubMedGoogle Scholar
  • 11 Popp B, Trollmann R, Büttner C. et al Do the exome: A case of Williams-Beuren syndrome with severe epilepsy due to a truncating de novo variant in GABRA1. Eur J Med Genet 2016; 59: 549-553
    CrossrefPubMedGoogle Scholar
  • 12 Riikonen R, Rener-Primec Z, Carmant L. et al Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol 2015; 57: 60-67
    CrossrefPubMedGoogle Scholar
  • 13 O'Callaghan FJK, Edwards SW, Alber FD. et al Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health 2018; 2: 715-725
    CrossrefPubMedGoogle Scholar
  • 14 Samueli S, Dressler A, Gröppel G. et al Everolimus in infants with tuberous sclerosis complex-related West syndrome: First results from a single-center prospective observational study. Epilepsia 2018; 59: e142-e146
    CrossrefPubMedGoogle Scholar
  • 15 French JA, Lawson JA, Yapici Z. et al Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388: 2153-2163
    CrossrefPubMedGoogle Scholar
  • 16 Riikonen R. Infantile spasms: outcome in clinical studies. Pediatr Neurol 2020; 20: 30041-30042
    PubMedGoogle Scholar
  • 17 Yuskaitis CJ, Ruzhnikov MRZ, Howell KB. et al. Infantile spasms of unknown cause: predictors of outcome and genotype-phenotype correlation. Pediatr Neurol 2018 pii S0887-8994(18):30346–30341
    PubMed
  • 18 Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011; 52: 3-9
    CrossrefPubMedGoogle Scholar
  • 19 Gataullina S, Dulac O. Is epilepsy the cause of comorbidities in Dravet syndrome?. Dev Med Child Neurol 2018; 60: 8
    CrossrefPubMedGoogle Scholar
  • 20 Nabbout R, Chemaly N, Chipaux M. et al Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis 2013; 8: 176
    CrossrefPubMedGoogle Scholar
  • 21 Bureau M, Dalla Bernardina B. Electroencephalographic characteristics of Dravet syndrome. Epilepsia 2011; 52: 13-23
    CrossrefPubMedGoogle Scholar
  • 22 Jensen HS, Grunnet M, Bastlund JF. Therapeutic potential of Na(V)1.1 activators. Trends Pharmacol Sci 2014; 35: 113-118
    CrossrefPubMedGoogle Scholar
  • 23 Balagura G, Cacciatore M, Grasso EA. et al Fenfluramine for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome. CNS Drugs 2020; 34: 1001-1007
    CrossrefPubMedGoogle Scholar
  • 24 Lagae L. Dravet syndrome. Curr Opin Neurol 2021; 34: 213-218 doi: 10.1097/WCO.0000000000000902
    CrossrefPubMedGoogle Scholar
  • 25 Barba C, Parrini E, Coras R. et al Co-occurring malformations of cortical development and SCN1A gene mutations. Epilepsia 2014; 55: 1009-1019
    CrossrefPubMedGoogle Scholar
  • 26 Tiefes AM, Hartlieb T, Tacke M. et al Mesial Temporal Sclerosis in SCN1A-Related Epilepsy: Two Long-Term EEG Case Studies. Clin EEG Neurosci 2019; 50: 267-272
    CrossrefPubMedGoogle Scholar
  • 27 Skjei KL, Church EW, Harding BN. et al Clinical and histopathological outcomes in patients with SCN1A mutations undergoing surgery for epilepsy. J Neurosurg Pediatr 2015; 16: 668-674
    CrossrefPubMedGoogle Scholar
  • 28 Cross JH, Auvin S, Falip M. et al Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol 2017; 8: 505
    CrossrefPubMedGoogle Scholar
  • 29 Arzimanoglou A, French J, Blume WT. et al Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009; 8: 82-93
    CrossrefPubMedGoogle Scholar
  • 30 Lammertse HCA, van Berkel AA, Iacomino M. et al Homozygous STXBP1 variant causes encephalopathy and gain-of-function in synaptic transmission. Brain 2020; 143: 441-451
    CrossrefPubMedGoogle Scholar
  • 31 Hammer MF, Wagnon JL, Mefford HC. et al SCN8A-Related Epilepsy with Encephalopathy. 2016 Aug 25. In: Adam MP, Ardinger HH, Pagon RA, et al. (eds) GeneReviews® [Internet]. Seattle (WA), University of Washington, Seattle; 1993–2021
    PubMed
  • 32 Mastrangelo M. Lennox-Gastaut Syndrome: A State of the Art Review. Neuropediatrics 2017; 48: 143-151
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Jiang X, Raju PK, D'Avanzo N. et al Both gain-of-function and loss-of-function de novo CACNA1A mutations cause severe developmental epileptic encephalopathies in the spectrum of Lennox-Gastaut syndrome. Epilepsia 2019; 60: 1881-1894
    CrossrefPubMedGoogle Scholar
  • 34 Verrotti A, Grasso EA, Cacciatore M. et al. Potential role of brivaracetam in pediatric epilepsy. Acta Neurol Scand 2020
    PubMed
  • 35 Strzelczyk A, Schubert-Bast S. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies. CNS Drugs 2021
    PubMed
  • 36 Devinsky O, Patel AD, Cross JH. et al GWPCARE3 Study Group. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med 2018; 378: 1888-1897
    CrossrefPubMedGoogle Scholar
  • 37 Suller Marti A, Mirsattari SM, MacDougall K. et al Vagus nerve stimulation in patients with therapy-resistant generalized epilepsy. Epilepsy Behav 2020; 111: 107253
    CrossrefPubMedGoogle Scholar
  • 38 Landau WM, Kleffner FR. Syndrome of acquired aphasia with convulsive disorder in children. Neurology 1957; 7: 523-530
    CrossrefPubMedGoogle Scholar
  • 39 Deonna T. Acquired epileptiform aphasia in children (Landau-Kleffner-Syndrome). J Clin Neurophysiol 1991; 8: 288-298
    CrossrefPubMedGoogle Scholar
  • 40 Morell F, Lewine JD, Squires K. Magnetic source imaging in Landau-Kleffner-Syndrome and its LJS loo-alikes. Epilepsia 1995; 32: 13
    PubMedGoogle Scholar
  • 41 Hoeppner TJ, Morell F, Smith MC. et al The Landau-Kleffner-Syndrome: A perisylvian epilepsy. Epilepsia 1992; 33 (Suppl 3): 122
    CrossrefPubMedGoogle Scholar
  • 42 Rismanchi M. The inhibitory effect of functional lesions on eloquent brain areas: from research bench to operating bed. Int J Neurosci 2018; 128: 1022-1029 doi:10.1080/00207454.2018.1458726. 10.1080/00207454.2018.1458726
    CrossrefPubMedGoogle Scholar
  • 43 Carvill GL, Regan BM, Yendle SC. et al GRIN2A mutations cause epilepsy aphasia spectrum disorders. Nat Genet 2013; 45: 1073-1076. doi:10.1038/ng.2727
    CrossrefPubMedGoogle Scholar
  • 44 Lesca G, Rudolf G, Bruneau N. et al GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet 2013; 45: 1061-1066. doi:10.1038/ng.2726
    CrossrefPubMedGoogle Scholar
  • 45 Mefford H, Yendle S, Hsu C. et al Rare copy number variants are an important cause of epileptic encephalopathies. Ann Neurol 2011; 70: 974-985. doi:10.1002/ana.22645
    CrossrefPubMedGoogle Scholar
  • 46 Rudolf G, de Bellescize J, de Saint Martin A. et al Exome sequencing in 57 patients with self-limited focal epilepsies in childhood with typical or atypical presentations suggest novel candidate genes. Eur J Pediatric Neurol 2020; 27: 104-110
    CrossrefPubMedGoogle Scholar
  • 47 Bast T, Richter S, Ebinger F. et al Efficacy and tolerability of methylprednisolone pulse therapy in childhood epilepsies other than infantile spasms. Neuropediatrics 2014; 45: 378-385 doi:10.1055/s-0034-1387817
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Van den Munckhof B, van Dee V, Sagi L. et al Treatment of electrical status epilepticus in sleep: A pooled analysis of 575 cases. Epilepsia 2015; 56: 1738-1746 doi:10.1111/epi.13128
    CrossrefPubMedGoogle Scholar
  • 49 Downes M, Greenaway R, Clark M. et al Outcome following multiple subpial transection in Landau-Kleffner syndrome and related regression. Epilepsia 2015; 56: 1760-1766 doi:10.1111/epi.13132
    CrossrefPubMedGoogle Scholar